Assurance de qualité pour le cancer rectal – phase 2 ...

40 PROCARE – phase 2 KCE reports 81In the administrative cohort 99% (95%CI 98 – 100%) of the cStage II-III patients thatunderwent surgery and received neoadjuvant chemoradiotherapy, received achemotherapy regimen with 5-FU (Table 28). For 78 patients, no information wasavailable on the received treatment. Above this, for 3520 of the 5677 patientsundergoing radical surgery, no information was available on the cStage (total missings:3598/7074, 51%).Prospective data were available from 16 centres, with a range of 1 – 13 eligible patientsper centre. Fourteen centres had a score of 100%.This QI was measurable for 91 centres using the administrative database. Again, littlevariation can be found, with 89 of the 91 centres scoring 100%. Importantly, 80 centrestreated less than 10 eligible patients.Table 27. Number of patients that received neoadjuvant chemoradiotherapywith 5-FU, measured with prospective PROCARE data.cStageI II III X II-IIIPatients with rectal cancer 107 160 357 335 517Patients with rectal cancer that underwent surgery 107 160 356 330 516Patients that received neoadjuvant chemoradiotherapy 11 53 237 127 290Patients with known regimen (denominator) 2 12 51 4 63Patients with 5-FU (numerator) 2 12 48 4 60 (95%)Table 28. Proportion of patients that received neoadjuvantchemoradiotherapy with 5-FU, measured with administrative data.cStageI II III X II-IIIPatients with rectal cancer 438 790 807 4392 1597Patients with rectal cancer that underwent surgery 392 709 733 3521 1442Proportion with known regimen (denominator) 31 206 383 497 589Proportion with 5-FU (numerator) 31 206 382 496 588 (99%)Proportion of cStage II-III patients treated with neoadjuvant 5-FUbased chemoradiation, that received a continuous infusion of 5-FUDEFINITIONNumerator: all patients with cStage II or III RC that underwent surgery and that receivedneoadjuvant CRT with a regimen containing 5-FU via continuous infusion.Denominator: all patients with cStage II or III RC that underwent surgery and thatreceived neoadjuvant CRT with a regimen containing 5-FU.Exclusion:• patients with cStage other than II and III• cStage II and III patients not treated with surgery• cStage II and III patients receiving neoadjuvant radiotherapy orchemotherapy as a monotherapy• cStage II-III patients not receiving 5-FU based neoadjuvantchemoradiotherapyRESULTSDue to the absence of a specific code for the administration of a continuous infusion of5-FU, this QI is not measurable in both the prospective and administrative cohort.